Newer hormonal pharmacotherapies for heart failure

Srikanth Yandrapalli, George Jolly, Medha Biswas, Yogita Rochlani, Prakash Harikrishnan, Wilbert S. Aronow, Gregg M. Lanier

Research output: Contribution to journalReview article

Abstract

Introduction: Heart failure (HF) is characterized by maladaptive neurohormonal activation of the cardiovascular and renal systems resulting in circulatory inadequacy and frequent acute exacerbations. The increasing burden of HF prompted investigation of underlying pathophysiological mechanisms and the design of pharmacotherapeutics that would target these pathways. Areas covered: A MEDLINE search for relevant original investigations and review articles of newer hormonal drugs for HF since the year 2005 till October 2017 provided us with necessary literature. Major trials and relevant clinical investigations were discussed. Expert commentary: A multitude of hormonal pathways central to HF were identified, including the natriuretic peptide system and neurohormones such as relaxin, arginine vasopressin, and endothelin. However, drugs targeting these novel pathways (aliskiren, tolvaptan, ularitide, serelaxin, bosentan, macitentan) failed to show mortality benefit. This emphasizes a tremendous unmet need in the pharmacotherapy for HF, especially for the subtypes of acute HF and HF with preserved ejection fraction. Sacubitril/valsartan demonstrated substantial mortality benefit in chronic systolic HF population and is endorsed by international HF guidelines. If proven to be efficacious in larger outcome trials, finerenone can be a valuable addition baseline HF therapy. More basic, translational, and phenotype specific clinical research is warranted to improve HF pharmacotherapy.

Original languageEnglish (US)
Pages (from-to)35-49
Number of pages15
JournalExpert Review of Endocrinology and Metabolism
Volume13
Issue number1
DOIs
StatePublished - Jan 2 2018
Externally publishedYes

Fingerprint

Heart Failure
Drug Therapy
Systolic Heart Failure
Relaxin
Natriuretic Peptides
Mortality
Arginine Vasopressin
Endothelins
Drug Delivery Systems
Cardiovascular System
MEDLINE
Neurotransmitter Agents
Clinical Trials
Guidelines
Phenotype
Kidney
Research
Pharmaceutical Preparations
Population

Keywords

  • Aliskiren
  • finerenone
  • heart failure
  • nesiritide
  • novel pharmacotherapy
  • sacubitril/valsartan
  • serelaxin
  • tolvaptan
  • ularitide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Yandrapalli, S., Jolly, G., Biswas, M., Rochlani, Y., Harikrishnan, P., Aronow, W. S., & Lanier, G. M. (2018). Newer hormonal pharmacotherapies for heart failure. Expert Review of Endocrinology and Metabolism, 13(1), 35-49. https://doi.org/10.1080/17446651.2018.1406799

Newer hormonal pharmacotherapies for heart failure. / Yandrapalli, Srikanth; Jolly, George; Biswas, Medha; Rochlani, Yogita; Harikrishnan, Prakash; Aronow, Wilbert S.; Lanier, Gregg M.

In: Expert Review of Endocrinology and Metabolism, Vol. 13, No. 1, 02.01.2018, p. 35-49.

Research output: Contribution to journalReview article

Yandrapalli, S, Jolly, G, Biswas, M, Rochlani, Y, Harikrishnan, P, Aronow, WS & Lanier, GM 2018, 'Newer hormonal pharmacotherapies for heart failure', Expert Review of Endocrinology and Metabolism, vol. 13, no. 1, pp. 35-49. https://doi.org/10.1080/17446651.2018.1406799
Yandrapalli S, Jolly G, Biswas M, Rochlani Y, Harikrishnan P, Aronow WS et al. Newer hormonal pharmacotherapies for heart failure. Expert Review of Endocrinology and Metabolism. 2018 Jan 2;13(1):35-49. https://doi.org/10.1080/17446651.2018.1406799
Yandrapalli, Srikanth ; Jolly, George ; Biswas, Medha ; Rochlani, Yogita ; Harikrishnan, Prakash ; Aronow, Wilbert S. ; Lanier, Gregg M. / Newer hormonal pharmacotherapies for heart failure. In: Expert Review of Endocrinology and Metabolism. 2018 ; Vol. 13, No. 1. pp. 35-49.
@article{076f3bdd896b4f9190b0cc4e9ec769c0,
title = "Newer hormonal pharmacotherapies for heart failure",
abstract = "Introduction: Heart failure (HF) is characterized by maladaptive neurohormonal activation of the cardiovascular and renal systems resulting in circulatory inadequacy and frequent acute exacerbations. The increasing burden of HF prompted investigation of underlying pathophysiological mechanisms and the design of pharmacotherapeutics that would target these pathways. Areas covered: A MEDLINE search for relevant original investigations and review articles of newer hormonal drugs for HF since the year 2005 till October 2017 provided us with necessary literature. Major trials and relevant clinical investigations were discussed. Expert commentary: A multitude of hormonal pathways central to HF were identified, including the natriuretic peptide system and neurohormones such as relaxin, arginine vasopressin, and endothelin. However, drugs targeting these novel pathways (aliskiren, tolvaptan, ularitide, serelaxin, bosentan, macitentan) failed to show mortality benefit. This emphasizes a tremendous unmet need in the pharmacotherapy for HF, especially for the subtypes of acute HF and HF with preserved ejection fraction. Sacubitril/valsartan demonstrated substantial mortality benefit in chronic systolic HF population and is endorsed by international HF guidelines. If proven to be efficacious in larger outcome trials, finerenone can be a valuable addition baseline HF therapy. More basic, translational, and phenotype specific clinical research is warranted to improve HF pharmacotherapy.",
keywords = "Aliskiren, finerenone, heart failure, nesiritide, novel pharmacotherapy, sacubitril/valsartan, serelaxin, tolvaptan, ularitide",
author = "Srikanth Yandrapalli and George Jolly and Medha Biswas and Yogita Rochlani and Prakash Harikrishnan and Aronow, {Wilbert S.} and Lanier, {Gregg M.}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/17446651.2018.1406799",
language = "English (US)",
volume = "13",
pages = "35--49",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Newer hormonal pharmacotherapies for heart failure

AU - Yandrapalli, Srikanth

AU - Jolly, George

AU - Biswas, Medha

AU - Rochlani, Yogita

AU - Harikrishnan, Prakash

AU - Aronow, Wilbert S.

AU - Lanier, Gregg M.

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Heart failure (HF) is characterized by maladaptive neurohormonal activation of the cardiovascular and renal systems resulting in circulatory inadequacy and frequent acute exacerbations. The increasing burden of HF prompted investigation of underlying pathophysiological mechanisms and the design of pharmacotherapeutics that would target these pathways. Areas covered: A MEDLINE search for relevant original investigations and review articles of newer hormonal drugs for HF since the year 2005 till October 2017 provided us with necessary literature. Major trials and relevant clinical investigations were discussed. Expert commentary: A multitude of hormonal pathways central to HF were identified, including the natriuretic peptide system and neurohormones such as relaxin, arginine vasopressin, and endothelin. However, drugs targeting these novel pathways (aliskiren, tolvaptan, ularitide, serelaxin, bosentan, macitentan) failed to show mortality benefit. This emphasizes a tremendous unmet need in the pharmacotherapy for HF, especially for the subtypes of acute HF and HF with preserved ejection fraction. Sacubitril/valsartan demonstrated substantial mortality benefit in chronic systolic HF population and is endorsed by international HF guidelines. If proven to be efficacious in larger outcome trials, finerenone can be a valuable addition baseline HF therapy. More basic, translational, and phenotype specific clinical research is warranted to improve HF pharmacotherapy.

AB - Introduction: Heart failure (HF) is characterized by maladaptive neurohormonal activation of the cardiovascular and renal systems resulting in circulatory inadequacy and frequent acute exacerbations. The increasing burden of HF prompted investigation of underlying pathophysiological mechanisms and the design of pharmacotherapeutics that would target these pathways. Areas covered: A MEDLINE search for relevant original investigations and review articles of newer hormonal drugs for HF since the year 2005 till October 2017 provided us with necessary literature. Major trials and relevant clinical investigations were discussed. Expert commentary: A multitude of hormonal pathways central to HF were identified, including the natriuretic peptide system and neurohormones such as relaxin, arginine vasopressin, and endothelin. However, drugs targeting these novel pathways (aliskiren, tolvaptan, ularitide, serelaxin, bosentan, macitentan) failed to show mortality benefit. This emphasizes a tremendous unmet need in the pharmacotherapy for HF, especially for the subtypes of acute HF and HF with preserved ejection fraction. Sacubitril/valsartan demonstrated substantial mortality benefit in chronic systolic HF population and is endorsed by international HF guidelines. If proven to be efficacious in larger outcome trials, finerenone can be a valuable addition baseline HF therapy. More basic, translational, and phenotype specific clinical research is warranted to improve HF pharmacotherapy.

KW - Aliskiren

KW - finerenone

KW - heart failure

KW - nesiritide

KW - novel pharmacotherapy

KW - sacubitril/valsartan

KW - serelaxin

KW - tolvaptan

KW - ularitide

UR - http://www.scopus.com/inward/record.url?scp=85039152384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039152384&partnerID=8YFLogxK

U2 - 10.1080/17446651.2018.1406799

DO - 10.1080/17446651.2018.1406799

M3 - Review article

C2 - 30063443

AN - SCOPUS:85039152384

VL - 13

SP - 35

EP - 49

JO - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 1

ER -